Company Information
- Type:
- Company
- Country:
- Japan
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 31 March 2009 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2024
Financial Information
Non-Financial Information
Engagements
Affiliated Subsidiaries
| Country | Company Name |
|---|---|
| Switzerland | Takeda Pharmaceuticals International AG |
| India | Baxalta Bioscience India Pvt Limited |
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 16-Dec-2022 | 2022 Annual Integrated Report | Active |
| 20-Dec-2021 | 2021 Annual Integrated Report | Learner |
| 25-Dec-2020 | 2020 Sustainability Report | Active |
| 14-Jan-2020 | Sustainable Value Report 2019 | Active |
| 31-Jul-2019 | Grace Letter | Not applicable |
| 30-Oct-2018 | Sustainable Value Report 2018 | Advanced |
| 30-Oct-2017 | Sustainable Value Report 2017 | Advanced |
| 31-Oct-2016 | Communication on Progress | Advanced |
| 02-Nov-2015 | Communication on Progress | Advanced |
| 04-Nov-2014 | Communication on Progress | Advanced |
| 10-Nov-2013 | Communication on Progress | Advanced |
| 09-Nov-2012 | Communication on Progress | Advanced |
| 08-Dec-2011 | Annual Report 2011/ CSR Databook 2011 | Advanced |
| 08-Dec-2010 | 2010 Communication on Progress | Not applicable |
| 08-Dec-2009 | 2009 CSR Databook | Not applicable |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.